Comparative Pharmacology
Head-to-head clinical analysis: DICYCLOMINE HYDROCHLORIDE versus FRINDOVYX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DICYCLOMINE HYDROCHLORIDE versus FRINDOVYX.
DICYCLOMINE HYDROCHLORIDE vs FRINDOVYX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of muscarinic acetylcholine receptors, inhibiting parasympathetic nerve impulses in the gastrointestinal tract, leading to smooth muscle relaxation.
Frindovyx is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the central nervous system by inhibiting the reuptake of serotonin at the synaptic cleft.
10-20 mg orally 3-4 times daily
10 mg orally once daily.
None Documented
None Documented
1.8 to 2.5 hours (terminal half-life, shorter in younger patients)
Terminal elimination half-life is 12-15 hours in patients with normal renal function; prolonged to 24-30 hours in moderate renal impairment (CrCl 30-50 mL/min) and up to 48 hours in severe impairment (CrCl <30 mL/min).
Renal (∼79.5% as unchanged drug and metabolites) with minor biliary/fecal elimination (∼8-10%)
Renal excretion of unchanged drug accounts for approximately 60% of the administered dose, with an additional 30% recovered as inactive metabolites in urine. Fecal/biliary elimination constitutes the remaining 10%.
Category A/B
Category C
Anticholinergic
Anticholinergic